Clinical trials are designed with precision. They are executed in variability. Enrollment curves rarely follow projections. Screen failure rates shift. Sites activate at different speeds across regions. Protocol amendments introduce new cohorts or dosing changes. Manufacturing timelines adjust. Forecasts drift.
In this environment, technology alone is not enough. Systems generate data. They do not interpret volatility.
This is why Drug Supply Managers have become the operational backbone of modern clinical supply.
Forecasting Is a Starting Point, Not a Prediction
Every clinical trial begins with a forecast. Enrollment assumptions are modeled. Site activation schedules are estimated. Manufacturing campaigns are planned. Inventory buffers are calculated. Shipment strategies are approved.
At study startup, these forecasts often appear precise. Yet every forecast is built upon assumptions about future behavior, and clinical trials are fundamentally human systems. Patients do not enroll according to spreadsheets. Investigators do not recruit at identical rates. Protocol amendments do not announce themselves years in advance.
A forecast may estimate a 15% screen failure rate. Reality may produce 25%. A region expected to contribute 30% of enrollment may contribute 50%. A manufacturing delay of two weeks may suddenly reduce available shelf-life across multiple countries.
None of these events indicate that the original forecast was wrong. They simply reflect the reality that clinical trials operate in a constantly changing environment. This is why the most successful sponsors treat forecasting as a living process rather than a one-time exercise. The value of forecasting is not that it predicts the future perfectly. The value of the forecasting is that it provides a baseline against which change can be measured.
Drug Supply Managers are responsible for recognizing when reality begins to diverge from the baseline and determining what actions are required to maintain continuity.
From Logistics Coordinator to Strategic Supply Partner
Drug Supply Management is often misunderstood as a coordination role. In reality, it functions as the control center of the clinical supply chain.
DSMs sit at the intersection of IRT configuration, depot operations, manufacturing cadence, site demand, and sponsor expectations. They do not simply track shipments. They actively manage risk.
Sponsors tend to recognize the importance of DSMs when something goes wrong. A site runs short. An emergency shipment is triggered. Excess inventory expires on the shelf. Blinding is threatened by uneven resupply patterns.
Strong DSM oversight prevents those moments from occurring in the first place.
The Evolution of Drug Supply Management
The role of the Drug Supply Manager has evolved significantly over the past decade. Historically, supply management focused heavily on inventory coordination and shipment execution. Modern clinical trials demand far more.
Today’s studies frequently involve adaptive designs, global enrollment, direct-to-patient strategies, multiple depots, country-specific regulations, temperature-sensitive products, complex blinding requirements, and rapidly changing enrollment dynamics. As complexity has increased, so has the need for operational oversight.
Modern DSMs function as supply strategists as much as supply managers. They combine data from IRT systems, enrollment reports, manufacturing schedules, depot inventories, and operational trends to provide a real-time view of study health. Their role is no longer limited to moving inventory. Their role is maintaining equilibrium across a dynamic and interconnected supply chain.
In many ways, Drug Supply Management has become the operational bridge between the protocol anticipated and what the study is actually experiencing.
The more complex the trial becomes, the more valuable that bridge becomes.
Continuous Oversight Across Depots and Sites
Global clinical trials operate across multiple depots, regions, and site types. Each node in that network introduces variability.
A DSM maintains continuous visibility across:
- Depot inventory levels
- Site stock positions
- Shipment cadence
- Enrollment velocity by region
- Buffer thresholds
This is not static reporting. It is active monitoring. Weekly reviews identify emerging imbalances before they become critical. If one region enrolls faster than projected, supply parameters are adjusted. If another lags, excess inventory can be redirected. Depot-to-depot transfers are coordinated strategically rather than reactively.
The objective is simple: ensure each site has exactly what it needs, no more and no less. Right-sized inventory reduces waste, lowers carrying costs, and protects patients from dosing interruptions. Strategic supply planning in large global programs has demonstrated measurable cost avoidance by optimizing shipment schedules and reducing urgent logistics events. More importantly, it reduces operational strain across the study team.
IRT Is Not Set-and-Forget
Interactive Response Technology is powerful, but it is not autonomous. Resupply triggers, buffer levels, shipment quantities, and forecasting logic are configured based on assumptions at study start. As enrollment shifts, those assumptions may no longer hold. A DSM continuously evaluates whether system parameters still reflect operational reality.
For example:
- If screen failures rise, kit consumption slows.
- If a new cohort opens, demand accelerates in specific regions.
- If country activation staggers, supply imbalances emerge.
Without active oversight, IRT settings can generate excess shipments or fail to respond quickly enough to prevent shortfalls.
DSMs refine these parameters in collaboration with clinical operations, ensuring that system logic evolves alongside study behavior. This protects blinding integrity, stabilizes site inventory, and prevents costly emergency shipments.
Technology executes. DSMs interpret and adapt.
Preventing Shortfalls Before They Escalate
Shortages rarely happen overnight. They build gradually. A missed projection here. A delayed batch there. A spike in enrollment at a high-performing site. When no one monitors the system holistically, risk compounds quietly until it surfaces as a crisis.
DSMs operate upstream of the problem. They:
- Detect forecast drift early
- Adjust shipment frequency or quantities
- Coordinate manufacturing timing with anticipated demand
- Initiate ad hoc transfers before sites escalate
The goal is not to respond quickly. It is to eliminate the need for response. By stabilizing supply proactively, DSMs protect subject retention, reduce site burden, and preserve study credibility.
One Point of Accountability
Clinical supply involves multiple stakeholders: sponsors, CROs, depots, manufacturing sites, packaging facilities, and IRT providers. Communication can fragment easily. A DSM acts as a single operational point of accountability.
Instead of supply questions bouncing across teams, there is centralized oversight. Instead of isolated data points, there is contextual interpretation. Instead of reactive email chains, there is structured monitoring and coordinated action. This clarity reduces friction and accelerates decision-making. In complex global trials, accountability is not just convenient. It is protective.
The Cost of Getting it Wrong
Supply disruptions are often discussed as logistical problems. In reality, they are business problems.
When inventory arrives late, sites spend time escalating issues rather than enrolling patients. When emergency shipments become routine, transportation costs rise rapidly. When excess inventory accumulates at low-performing sites, sponsors absorb unnecessary waste. When supply assumptions are no longer aligned with study behavior teams become reactive instead of strategic.
The financial consequences can be substantial. Industry analyses consistently show that investigational product represents one of the largest direct costs within a clinical trial. Even small improvements in inventory utilization, shipment planning, and expiry management can generate significant savings across a global program.
The operational impact may be even greater. Supply interruptions can delay visits, create site burden and additional workload for clinical operations teams and introduce uncertainty into trial execution. Patients rarely see the underlying supply chain. They only experience the outcome.
For that reason, supply continuity is not merely a logistics objective. It is a patient retention strategy, a budget management strategy, and a trial execution strategy. Drug Supply Managers help ensure that operational issues remain invisible to patients and sites by identifying risks before they become visible disruptions.
Why DSMs Matter More Than Ever
The clinical environment continues to evolve. Trials are more global. Cohorts are more complex. Adaptive designs are more common. Timelines are tighter. Teams are leaner. In this context, Drug Supply Management is no longer a support function. It is a strategic safeguard.
DSMs:
- Stabilize volatile enrollment patterns
- Align IRT logic with real-world behavior
- Protect blinding through disciplined supply control
- Reduce waste without increasing risk
- Preserve dosing continuity across regions
Sponsors may not always see the work when it is done well. That is precisely the point. The strongest clinical supply chains are not defined by how quickly they react to disruption. They are defined by how rarely disruption occurs.
Technology moves product. Forecasting provides direction. Regulation protects patients. Drug Supply Management protects continuity. The strongest clinical supply chains are not defined by how quickly they recover from disruption. They are defined by how rarely disruption occurs. In today’s clinical environment, Drug Supply Management is no longer a support function. It is a strategic safeguard.
DSM Oversight:
For further reading on this topic:
- Supply Continuity in Clinical Trials: Why Certification Alone Is Not Enough
About the Authors
Melissa Peirsel is Manager of Global IRT Services at Sharp Clinical Services, where she leads the teams responsible for the delivery, validation, and operational support of clinical trial technology solutions for sponsors worldwide. With more than 13 years of experience in clinical research, she specializes in interactive response technology (IRT), RTSM, randomization and blinding strategy, clinical supply operations, quality systems, and operational oversight for complex global and early phase clinical trials.
Her work focuses on translating clinical and operational complexity into practical solutions that balance regulatory expectations with the realities faced by clinical sites. She believes successful study design should simplify operations, protect blinding, and ultimately help investigators focus on what matters most: delivering treatment safely and efficiently to patients. Read more of her work in our Expert Content on Sharp’s website.
Basem holds a Bachelor of Science degree from Penn State University.
